Quantcast
Last updated on April 18, 2014 at 0:12 EDT

Latest Chronic myelogenous leukemia Stories

2012-07-25 02:29:04

SUNNYVALE, Calif., July 25, 2012 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the release of an updated Xpert(®) BCR-ABL Monitor test, now incorporating lot-specific standardization using the WHO (World Health Organization) BCR-ABL standards. The test is being released as a European CE-IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. The test, which runs on Cepheid's GeneXpert(®) System, detects the BCR-ABL mRNA transcript in the...

2012-06-17 22:22:09

AMSTERDAM and CAMBRIDGE, Massachusetts, June 18, 2012 /PRNewswire/ -- ~ Robust anti-leukemic activity in CML patients who have become resistant or intolerant to available tyrosine kinase inhibitors ~ 54% major cytogenetic response and 30% major molecular response reported in heavily pre-treated chronic-phase CML patients ~ Data supports ARIAD filing for EMA approval of ponatinib in Europe ARIAD...

2012-06-15 10:23:01

PARIS, June 15, 2012 /PRNewswire/ -- Results Presented at 17th Congress of the European Hematology Association Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec(R)...

2012-06-01 10:22:07

NORTH WALES, Pa., June 1, 2012 /PRNewswire/ -- Teva Oncology presented two secondary analyses today featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that functions as a protein synthesis inhibitor at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago. These analyses were derived from data that was submitted to the US Food and Drug Administration as part of a new drug application (NDA) and was recently accepted for review.(4)...

2012-04-24 22:29:26

Although people generally talk about "cancer", it is clear that the disease occurs in a bewildering variety of forms. Even single groups of cancers, such as those of the white blood cells, may show widely differing properties. How do the various cancers arise and what factors determine their progression? Clues to these two issues, at least for leukemias, have now been provided by Boris Kovacic and colleagues at the University of Veterinary Medicine, Vienna (Vetmeduni Vienna). The results are...

2012-04-24 02:28:48

MISSISSAUGA, Ontario, April 24, 2012 /PRNewswire/ -- Kai Goulbourne is only eleven years old, but his life could be cut short if a matching bone marrow donor is not found soon. He was originally diagnosed in December of 2009, when his mom Shelley and Dad noticed, that despite having a healthy appetite, he appeared to be losing weight. Testing and examinations revealed an enlarged spleen, and he was diagnosed as having Chronic Myelogenous Leukemia. It is largely a genetic disorder where the...

2012-04-09 02:24:20

WASHINGTON, April 9, 2012 /PRNewswire-USNewswire/ -- A novel anti-leukemia compound with little toxicity successfully treated zebrafish with T-cell acute lymphoblastic leukemia (T-ALL), suggesting its potential to become a new highly targeted therapy for humans - even those resistant to conventional therapies - according to results from a study published online today in Blood, the Journal of the American Society of Hematology (ASH). T-ALL is a cancer of the white blood cells in which genetic...

2012-04-05 21:10:02

Researchers reporting in the April Cell Stem Cell, a Cell Press publication, have found a way to stop leukemia stem cells in their tracks. The advance in mice suggests that a combination approach to therapy might stamp out chronic myeloid leukemia (CML) for good. That's in contrast to the vast majority of CML patients taking drugs like imatinib (aka Gleevec) today, who often go into remission only to see their cancer return again. It is those lingering leukemia stem cells, which stubbornly...

2012-03-29 09:10:43

Change in registry protocols and laboratory practices cited Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues from the UF Shands Cancer Center in Gainesville, Fla., have found that cases of myeloid malignancies are being underreported since a change in registry protocols and laboratory practices starting in 2001. Their study is published in a recent issue of Cancer Epidemiology, Biomarkers and Prevention, a publication of the American Association for Cancer Research....

2012-03-19 05:13:45

A multi-national research team led by scientists at Duke-NUS Graduate Medical School has identified the reason why some patients fail to respond to some of the most successful cancer drugs. Tyrosine kinase inhibitor drugs (TKIs) work effectively in most patients to fight certain blood cell cancers, such as chronic myelogenous leukemia (CML), and non-small-cell lung cancers (NSCLC) with mutations in the EGFR gene. These precisely targeted drugs shut down molecular pathways that keep...